Buy & Sell Novartis AG (NVS) – Novartis AG Price Today
Aura AI Summary
Key Stats
- $288.46BMarket Cap
- HealthSector
- -14.34%3M Drawdown
- $328.48BEnterprise Value
- 3.14%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 80 daysTypical Hold Time
Novartis AG (NVS) is currently valued at a market capitalization of $288.46B, with an enterprise value of $328.48B. Over the past 52 weeks, Novartis AG has traded between a low of $111.87 and a high of $168.62, highlighting its annual price range. Over the past three months, Novartis AG has recorded a drawdown of -14.34%, reflecting recent price volatility. Novartis AG offers a dividend yield of 3.14%, with the most recent dividend of $4.77 paid on 11 Mar 26. On average, investors hold Novartis AG for approximately 80 days, indicating typical investor behavior on the platform.
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
